CervoMed Corporation - Multiplikator forward rega marang pendapatan CRVO

Logo perusahaan publik CervoMed Inc. (CRVO)

High FDA barriers and the cost of research protect the position of CervoMed Inc. (CRVO) in neuromedicine. Examining the forward P/S trajectory on GURU.Markets, it is evident that the value is maintained at 2542.40. Inelastic demand for neflamapimod provides pricing power, while a strict temperature-controlled delivery regime ensures therapy efficacy, confirming the business's growth potential.

CervoMed - Rasio kapitalisasi marang dodolan sing dikarepake CRVO (periode 21.02.2024 - 15.11.2026)

Ringkesan rincian data analitis CervoMed (CRVO)

Analisis komprehensif perusahaan:CervoMed Corporation CRVO
Sampel barang cervomed.com

To objectively assess the issuer's value, a portfolio manager must understand the forward P/S, which compares current market capitalization to expected revenue to measure the market premium for future growth. By analyzing changes in the forward P/S, an investor can gauge the level of priced-in optimism, which is critical for CervoMed Inc. (CRVO) due to the high sensitivity of its valuation to the outcomes of clinical trials for dementia drugs.

Pesaing CervoMed Inc. (CRVO)

Multiplikator Forward P/S BIIB (Biogen Idec)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine Corp (NBIX)|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Therapeutics)|ACAD: Multiplikator Forward P/S|Xenon Pharmaceuticals Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Viking Pharma|SUPN: Rega forward marang dodolan|Multiplikator Forward P/S CPRX|Multiplikator Forward P/S denalitherapeutics.com (DNLI)|Multiplikator Forward P/S HRMY (Harmony Biosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Biohaven (BHVN)|Amylyx Corp - Multiplikator Forward P/S|TRVI - Multiplikator Forward P/S|Praxis Precision Medicines Inc (PRAX) - Rasio rega marang prakiraan pendapatan|AVXL - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CeriBell|Multiplikator Forward P/S Prothena Corporation plc|Rasio rega marang prakiraan pendapatan Alector Therapeutics (ALEC)|Annexon Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan omeros.com OMER|neurogene.com (NGNE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|acimmune.com - Multiplikator Forward P/S|Voyager Therapeutics Inc (VYGR) - Multiplikator forward rega marang pendapatan|Neumora Corp (NMRA) - Rasio rega marang prakiraan pendapatan|Scilex Holding Company, Inc. (SCLX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan TVGN|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alpha Cognition Inc. ACOG|Rasio rega marang prakiraan pendapatan cogrx.com (CGTX)|Rasio kapitalisasi marang dodolan sing dikarepake Inhibikase Therapeutics, Inc.|Multiplikator Forward P/S SAVA (Cassava Sciences Inc)|Multiplikator Forward P/S Assertio Holdings, Inc. ASRT|COYA - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan Vistagen (VTGN)|OVID: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Acumen Pharmaceuticals Inc. (ABOS)|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc)|Multiplikator Forward P/S jupiterneurosciences.com (JUNS)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|Grace Tx - Multiplikator Forward P/S|AIFF (Firefly Neuroscience Inc) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan metaviatx.com (MTVA)|Multiplikator Forward P/S NRXS|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Passage Bio, Inc. - Multiplikator forward rega marang pendapatan|bionomics.com.au (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva - Multiplikator Forward P/S|Rega forward marang dodolan ATHA (Athira Pharma Inc)|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|PTIX (Protagenic Therapeutics) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake Cortigent|Multiplikator Forward P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|Cara Therapeutics Inc. - Multiplikator Forward P/S|Chromocell Therapeutics (CHRO) - Multiplikator forward rega marang pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator Forward P/S|Marinus - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO (NeuroBo Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S SAGE (Sage Therapeutics Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Synaptogenix Inc. (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|vigilneuro.com (VIGL) - Multiplikator forward rega marang pendapatan|WENA: Multiplikator Forward P/S|Cerevel Therapeutics, Inc. (CERE) - Multiplikator Forward P/S